SNSE today

$13.85+$0.85 (+6.54%)close Jun 15, 2026

Trend

—

Key levels

Resistance$18.60

Resistance$15.48

Support$10.78

Support$7.45

Latest news & SEC filings

No headlines in the last 90 days.

Nasdaq · Healthcare

Faeth Therapeutics, Inc. (SNSE)

$13.85+0.85 (+6.54%)
WATCHLISTGrade: BRisk: MEDIUM
1D5D1M1Y5YMaxSign up for all timeframes
13.9717.1520.3423.5213.85May 12May 20May 29Jun 8
High16.52
Low13.76
Open15.21
Volume206K
Avg Vol39K
VWAP14.49
30d High26.70
30d Low10.79
30d Chg-48.13%
See full chart with real-time data

What Is the Price Target for SNSE?

SEPT Low Target

$46.75

SEPT Mid Target

$55.00

SEPT High Target

$63.25

Analyst Consensus

$55.00

Current: $13.85Upside: +297.1%Confidence: 65%Method: Analyst Consensus

Is SNSE a Buy or Sell Right Now?

55
Investability Score
WATCHLIST12-18 months

Thesis

    AI-Powered Trading Signals

    Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SNSE.

    Start Free Trial →

    Is SNSE Overvalued or Undervalued?

    Valuation Verdict

    UNDERVALUED

    Methods Used

    P/B, Analyst Consensus

    Fair Value

    $44.71

    17

    Moat Score

    NONE

    1/9

    Piotroski Score

    -17.1

    Altman Z-Score

    What Is Smart Money Doing with SNSE?

    Insider Signal

    NEUTRAL

    4 buys / 16 sells (90d)

    Congress Signal

    NEUTRAL

    0 buys / 0 sells (90d)

    Institutional

    DISTRIBUTING

    Short Squeeze Risk

    LOW

    Signal: NEUTRAL

    Recent Insider Activity

    NameTitleTypeSharesValueDate
    Cambrian BioPharma Inc10% ownerSale24,524$490KJun 1, 2026
    Cambrian BioPharma Inc10% ownerSale476$10KJun 1, 2026
    Peyer James10% ownerSale24,524$490KJun 1, 2026
    Peyer James10% ownerSale476$10KJun 1, 2026

    Track Smart Money Across 4,000+ Stocks

    Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

    See All Smart Money Signals →

    SNSE Growth Story

    Revenue YoY

    N/A%

    3yr Revenue CAGR

    N/A%

    EPS Growth YoY

    30.36%

    FCF Growth YoY

    17.5%

    Revenue Trend

    UNKNOWN

    Full AI Research Report

    SEPT's Trading AI has generated a free, downloadable PDF research report for Faeth Therapeutics, Inc. (SNSE) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

    Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...

    Sign Up Free — Download AI Report PDF →

    AI-Powered Trading Signals.

    Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

    Try SEPT Free for 7 Days →

    Compare SEPT with other platforms

    SEPT vs TradingViewSEPT vs BloombergSEPT vs Unusual WhalesSEPT vs SpotGammaSEPT vs TrendSpiderAI Trading Platforms Compared
    What is dark pool trading?How to read options flowGEX explainedSmart money trackingAI stock analysisEarn money on SEPT

    About SEPT Investing

    SEPT Investing tracks 13,000+ stocks with live charts, trend and key-level tracking, dark pool and options flow, insider and congress trades, SEC filings and news alerts.

    Disclaimer: This page is for informational purposes only. It does not constitute financial advice. Past performance does not guarantee future results. Always do your own research before making investment decisions.

    SNSE — frequently asked questions

    What is SNSE stock price today?

    Faeth Therapeutics, Inc. (SNSE) is at $13.85, up 6.54% (+$0.85) at the Jun 15, 2026 close.

    What is the SNSE price target?

    The average analyst price target for SNSE is $55.00, ranging from $50 to $55, based on 4 analysts. Latest: BTIG initiates on Jun 11, 2026.

    What do analysts rate SNSE?

    Analyst ratings for SNSE: 0 Buy, 6 Hold, 0 Sell — consensus Hold.

    Did SNSE beat earnings?

    SNSE last reported on May 15, 2026: EPS -$131.45 vs -$0.62 expected — a miss.

    Does SNSE pay a dividend?

    SNSE does not currently pay a dividend.

    What are SNSE support and resistance levels?

    Support: $10.78, $7.45. Resistance: $15.48, $18.60, $21.50.

    What are insiders doing with SNSE?

    Insider activity: NEUTRAL, 4 buys and 16 sells in the last 90 days.